A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Farlow, Martin, Anand, Ravi, Messina Jr, John, Hartman, Richard, Veach, Jeffrey·2000·European Neurology

DOI 10.1159/000008243

Cited by (333)

Items 201–300 of 333

Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials
Kelvin K.F. Tsoi, Hoyee W. Hirai, Joyce Y.C. Chan, Timothy C. Y. Kwok · 2015 · Journal of the American Medical Directors Association
Rivastigmine in Vascular Dementia
Shoona Vincent, Roger M. Lane · 2003 · International Psychogeriatrics
Is there a double standard when it comes to dementia care?
D Wilkinson · 2005 · International Journal of Clinical Practice
Therapeutic approaches to age-associated neurocognitive disorders
Ruth M. O'Hara, Christian Derouesné, Konstantinos Ν. Fountoulakis, Jerome Albert Yesavage · 2001 · Dialogues in Clinical Neuroscience
One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests
Alina Borkowska, Marzena Ziółkowska-Kochan, JANUSZ K. RYBAKOWSKI · 2005 · Human Psychopharmacology Clinical and Experimental
Molecular docking study on the “back door” hypothesis for product clearance in acetylcholinesterase
Laleh Alisaraie, Gregor Fels · 2005 · Journal of Molecular Modeling
Gastrointestinal Adverse Events in a General Population Sample of Nursing Home Residents Taking Cholinesterase Inhibitors
Anthony Hughes, Jonathan Musher, Simu K. Thomas, Kathleen Marie Beusterien, Bill Strunk, Stephen Arcona · 2004 · The Consultant Pharmacist
Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24‐Week Randomized Phase III Trial
Jinzhou Tian, Jing Shi, Tao Li, Lin Li, Zhiliang Wang, Xiaobin Li, Zhu Lv, Qingshan Zheng, Mingqing Wei, Yongyan Wang · 2017 · Evidence-based Complementary and Alternative Medicine
Long-term cholinesterase inhibitor therapy for Alzheimer's disease: Implications for long-term care
Sharon A. Brangman · 2003 · American Journal of Alzheimer s Disease & Other Dementias®
Alzheimer’s Treatment in Nursing Homes: Room for Improvement
Lory E. Bright-Long · 2005 · Journal of the American Medical Directors Association
Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications
Jean‐François Baladi, Peter Bailey, Sandra E. Black, Rémi W. Bouchard, Karl D. Farcnik, Serge G. Gauthier, Andrew Kertesz, Erich Mohr, Alain Robillard · 2000 · Clinical Therapeutics
Management of Mild to Moderate Alzheimer Disease
Greg L. Plosker, Gillian M. Keating · 2004 · Disease Management & Health Outcomes
Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Shivam Rajput, Rishabha Malviya, Shiv Bahadur, Dinesh Puri · 2023 · Current Pharmaceutical Design
Protective effects of polydatin amphiphilic chitosan nanocarriers against an aluminum chloride-induced model of Alzheimer’s disease in rats: relevance to its anti-inflammatory and antioxidant effects
Seyede Nazanin Zarneshan, Elham Arkan, Amir Kiani, Seyede Zahra Hosseini, Fatemeh Abbaszadeh, Sajad Fakhri · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease
Sakshi Painuli, Prabhakar Semwal, Wissam Zam, Yasaman Taheri, Shahira M. Ezzat, Peijun Zuo, Liping Li, Dileep Kumar, Javad Sharifi‐Rad, Natália Alves Martins · 2022 · Combinatorial Chemistry & High Throughput Screening
Combined treatment with Ginkgo biloba extract EGb 761 plus acetylcholinesterase inhibitors improved cognitive function and neuropsychiatric symptoms in patients with mild cognitive impairment
José María García‐Alberca, Esther Gris, Silvia Mendoza · 2022 · Alzheimer s & Dementia Translational Research & Clinical Interventions
Health economic analysis of the integrated cognitive assessment tool to aid dementia diagnosis in the United Kingdom
Judith Shore, Chris Kalafatis, Angela Stainthorpe, Mohammad Hadi Modarres, Seyed‐Mahdi Khaligh‐Razavi · 2023 · Frontiers in Public Health
Frontotemporal lobar degeneration: clinical and pathologic overview.
G. Rabinovici, K. Rascovsky, B. Miller · 2008 · Handbook of Clinical Neurology
Challenges of Longevity in Developed Countries: Vascular Prevention of Dementia as an Immediate Clue to Tackle an Upcoming Medical, Social and Economic Stretch
Martin Wehling, Hans Groth · 2011 · Neurodegenerative Diseases
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Gabriel C. Léger, Fadi Massoud · 2013 · Expert Review of Clinical Pharmacology
Evaluación de la conveniencia del cambio de vía de administración de rivastigmina en pacientes con enfermedad de Alzheimer
Rafael Blesa, Merçé Boada, C. Martínez Parra, Domènec Gil i Saladié, Carmen Antúnez Almagro, A.L. Gobartt Vázquez · 2011 · Neurología
Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease
Rafael Blesa, Merçé Boada, C. Martínez Parra, Domènec Gil i Saladié, Carmen Antúnez Almagro, A.L. Gobartt Vázquez · 2011 · Neurología (English Edition)
The Cholinesterase Inhibitors
Robert N. Rubey · 2003 · Journal of Psychiatric Practice
Improvement of spontaneous speech in early stage Alzheimer's disease with rivastigmine
Evy G Visch-Brink, W. Van Rhee-Temme, Toni C. M. Rietveld, Jaap W.M. Krulder, F. van Harskamp, Tischa J. M. van der Cammen · 2009 · The journal of nutrition health & aging
Cognitive issues in Parkinson's disease
Lawrence W. Elmer · 2004 · Neurologic Clinics
ALZHEIMER’S DISEASE AND ACETYLCHOLINESTERASE INHIBITOR AGENTS: A TWO-YEAR LONGITUDINAL STUDY
C. Fuschillo, E. ASCOLI, Giuseppina Franzese, F. CAMPANA, Christophe Cello, M. GALDI, Silvestro La Pia, C. CETRANGOLO · 2004 · Archives of Gerontology and Geriatrics
Effects of S-Adenosylmethionine on Cognition in Animals and Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Yan Mei Zhao, Yizhou Zhang, Sijia Meng, Bingyu Chen, Xinyi Dong, Xiaojing Guo, Fangzhen Guo, Runjiao Zhang, Huixian Cui, Sha Li · 2023 · Journal of Alzheimer s Disease
Recent Advances in the Treatment and Management of Alzheimer’s Disease: A Precision Medicine Perspective
Deepali Shukla, Anjali Suryavanshi, Sanjay Kumar Bharti, Vivek Asati, Debarshi Kar Mahapatra · 2024 · Current Topics in Medicinal Chemistry
When should drug treatment be started for people with dementia?
Baldev Singh, John Tiernan O'Brien · 2009 · Maturitas
Emerging Therapeutics for Alzheimer's Disease: An Avenue of Hope
Steven C. Samuels, Hillel T. Grossman · 2003 · CNS Spectrums
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease
Harish Kavirajan · 2005 · Neurology
New concepts in the drug therapy of Alzheimer’s disease
Martin Rhys Farlow, Ann Marie Hake · 2001 · Expert Opinion on Pharmacotherapy
The Effects of Galantamine Treatment on Attention and Its Relationship with Cognition and Activities of Daily Living in Patients with Mild to Moderate Alzheimer's Disease
Jae‐Hong Lee, Yun Jeong Hong, Hee‐Joon Bae, Beom Joon Kim, Duk-Lyul Na, Seol‐Heui Han, Jong‐Moo Park, Jee-Hyang Jeong, Kyung Ryeol Cha · 2015 · Journal of Clinical Neurology
Structural fingerprinting of pleiotropic flavonoids for multifaceted Alzheimer's disease
Amisha Punmiya, Arati Prabhu · 2023 · Neurochemistry International
Rationalizing Therapeutic Approaches in Alzheimer's Disease
George Thomas Grossberg · 2005 · CNS Spectrums
Alzheimer’s Disease – The Importance of Early Detection
Stephen Todd, Peter Passmore · 2008 · European Neurological Review
Long-Term Safety and Tolerability of Rivastigmine in Patients With Alzheimer's Disease Switched From Donepezil
Gary S. Figiel, Barbara Koumaras, Xiangyi Meng, John Strigas, İbrahim Günay · 2008 · The Primary Care Companion to The Journal of Clinical Psychiatry
The search for disease modification in moderate to severe Alzheimer disease
Martin Rhys Farlow · 2005 · Neurology
Therapeutic Uses of Cholinesterase Inhibitors in Neurodegenerative Diseases
Randall L. Woltjer, Dejan Milatović · 2006 · Elsevier eBooks
Mechanism and Molecular Targets of a Water-Soluble Extract of Artemisia annua on the Treatment of Alzheimer’s Disease Based on Network Pharmacology and Experimental Validation
Wenshu Zhou, Marta Silva, Chao Yang, Shuai Li, Yitian Chen, Wen-Hua Zheng · 2023 · The American Journal of Chinese Medicine
Doxorubicin as a Drug Repurposing for Disruption of α-Chymotrypsinogen-A Aggregates
Neha Kausar Ansari, Hamza Sahib Khan, Aabgeena Naeem · 2024 · The Protein Journal
Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer's Disease Dementia
Sun‐Wung Hsieh, Jui‐Cheng Chen, Nai-Ching Chen, Kai-Ming Jhang, Wenfu Wang, Yuan‐Han Yang · 2021 · Clinical Psychopharmacology and Neuroscience
Turning principles into practice in Alzheimer’s disease
James E. B. Lindesay, R. Morris Bullock, Hugo Daniëls, Murat Emre, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Pablo Martínez‐Lage, Andreas Urs Monsch, Magda Tsolaki et al. · 2010 · International Journal of Clinical Practice
The cognitive effects of cholinesterase inhibitor treatment in every-day practice
Elisabeth Kapaki, George P. Paraskevas · 2005 · Current Medical Research and Opinion
Cholinesterase inhibitors in the "real world" setting: rivastigmine versus donepezil tolerability and effectiveness study
Tomasz Sobów, Iwona Kłoszewska, Psychotic Disorders · 2006
Understanding Alzheimer disease
Muhammed Vally, Fatima Kathrada · 2019 · South African Family Practice
Prediction Models for Assessing Long-Term Outcome in Alzheimer’s Disease
Carina Wattmo · 2013 · American Journal of Alzheimer s Disease & Other Dementias®
A first principle study on the interaction between acetylcholinesterase and acetylcholine, and also rivastigmine in alzheimer's disease case
Vera Khoirunisa, Febdian Rusydi, Hideaki Kasai, A G Gandaryus, Hermawan Kresno Dipojono · 2016 · Journal of Physics Conference Series
Barriers to Alzheimer Disease Drug Discovery and Drug Development in the Pharmaceutical Industry
Ravi Anand · 2002 · Alzheimer Disease & Associated Disorders
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Jeffrey L. Cummings · 2004 · FOCUS The Journal of Lifelong Learning in Psychiatry
Future Demographic Challenges in Europe: The Urgency to Improve the Management of
H Groth, Reiner Klingholz, Martin Wehling · 2009
An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease
Mosaburo Kainuma, Shinji Ouma, Shinobu Kawakatsu, Osamu Iritani, Ken-Ichiro Yamashita, Tomoyuki Ohara, Shigeki Hirano, Shiro Suda, Tadanori Hamano, Sotaro Hieda et al. · 2022 · Frontiers in Pharmacology
Diagnosing and Treating Alzheimer's Disease: A Practitioner's Overview
Lorna Lou Schumann, Cynthia Langbart · 2002 · Journal of the American Academy of Nurse Practitioners
Clinical practice with anti-dementia drugs: a consensus statement from British Association for
Alistair S. Burns, Clive G. Ballard, Karl Broich, Howard Feldman, Gary A. Ford, Martin Richard John Knapp, Steve Iliffe, Roy W. Jones, Sean P. Lennon, Ian Grant McKeith et al. · 2006
Dementia: pharmacological and non-pharmacological treatments and guideline review
Martine Simard, Elizabeth Lesley Sampson · 2008 · Cambridge University Press eBooks
Donepezil‐ or rivastigmine‐induced acetylcholinesterase inactivation is not modulated by neramexane in rat brain
Ramesh C. Gupta, Andrzej Dekundy · 2007 · Drug Development Research
Long-Term Effects of Second-Generation Cholinesterase Inhibitors on Clinical Outcomes and Costs of Alzheimer???s Disease
J. Jaime, Denis Getsios · 2003 · Disease Management & Health Outcomes
Conventional Trial Designs Offer Limited Clinical Understanding of Cholinesterase-Inhibitor Treatment Effects in Alzheimer Disease
Michael Fraser Shanks, Annalena Venneri · 2005 · American Journal of Geriatric Psychiatry
Rivastigmine
Ezzat, Shahira M., Salem, Mohamed A., El Mahdy, Nihal M., Ragab, Mai F. · 2021 · Naturally Occurring Chemicals Against Alzheimer's Disease
Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis
Xiaoyan Deng, Daishun Li · 2024 · Medicine
Diagnostic Efficacy and Clinical Relevance of Artificial Intelligence in Detecting Cognitive Decline
Ali Ahmed Mohamed, O. Marques · 2023 · Cureus
Galantamine Delivery for Alzheimer’s Disease
Shweta Sharma · 2020 · Sustainable agriculture reviews
A probability formula derived from serum indicators, age, and comorbidities as an early predictor of dementia in elderly Chinese people
Qing Shan Gong, Lianhong Xie, Minghui Bi, Lina Yu · 2021 · Brain and Behavior
Reduction of acetylcholine in the hippocampus of hippocampal cholinergic neurostimulating peptide precursor protein knockout mice
Yuko Kondo, Masayuki Mizuno, Yo Tsuda, Yuta Madokoro, Kengo Suzuki, Toyohiro Sato, Hiroshi Takase, Yuto Uchida, Kenichi Adachi, Hideki Hida et al. · 2021 · Scientific Reports
Recognition and treatment of Alzheimer's disease: A case-based review
Dana M. Marseille, Daniel H.S. Silverman · 2006 · American Journal of Alzheimer s Disease & Other Dementias®
Rivastigmine in the Treatment of Alzheimer’s Disease
Dirk Deleu · 2001 · European Neurology
Donepezil in the treatment of mild to moderate Alzheimer's disease: report of a Belgian multicenter study.
Patrick Santens, Manfredi Ventura · 2003 · PubMed
Efficacy of medications in controlling cognitive dysfunction in Alzheimer’s : a systematic review
Sâmia Moreira de Andrade, Ítalo Sávio Mendes Rodrigues, Luís Marcelo Vieira Rosa, Rodrigo Luís Taminato, Gustavo Alves Andrade dos Santos · 2025 · Dementia & Neuropsychologia
The Pharmacological Treatment of Alzheimer's Disease with Cholinesterase Inhibitors and Memantine
Gordon Keith Wilcock · 2007 · Springer eBooks
Practical Principles for the Management of Alzheimer's Disease
Daniel D. Christensen · 2002 · The Primary Care Companion For CNS Disorders
La enfermedad de Alzheimer y los inhibidores de la colinesterasa
Calos L Alpizar Quesada, Catalina Morales Alpízar · 2009 · Acta Médica Costarricense
Current approaches to optimize treatment of dementia and Alzheimer's disease
Игорь Владимирович Колыхалов · 2016 · S S Korsakov Journal of Neurology and Psychiatry
Demenz
Jens Wiltfang, Sarah Trost, Harald-Jürgen Hampel · 2017 · Springer eBooks
Analysis of neuroprotective medication in patients with neurocognitive disorders: The efficacy and tolerability of highly purified animal tissues extracts
Octavian Vasiliu · 2022 · Romanian Journal of Military Medicine
Traitements médicamenteux des démences sévères
P. Jouanny, Serge Belliard, Danièle Bentué‐Ferrer, Olivier Michel, H. Allain · 2005 · Gériatrie et Psychologie Neuropsychiatrie du Viellissement
Reply to the Letter by Deleu: Rivastigmine in the Treatment of Alzheimer’s Disease
Martin Rhys Farlow · 2001 · European Neurology
Effectiveness of an integrative medicine approach to improve cognitive dysfunction and dementia: An observational study
Ji Hyun Lee, Man Gi Kim, Do Yeun Kim, Hyewon Shin, Hakmook Kang, Byung-Soo Koo, Kwang Ki Kim · 2022 · Medicine
Understanding and Treating Alzheimer’s Disease
Umesh Kumar, Alexander Roland, Stephen A. Burbidge · 2007 · Springer eBooks
Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Amie Taggart Blaszczyk, Monica L. Mathys · 2007 · Journal of Pharmacy Practice
Efectos de inhibidores de colinesterasa en pacientes con enfermedad asociada a cuerpos de Lewy
Nilton Custodio, Rosa Montesinos, Liliana Bendezú, Patricia Cortijo, Hernando Torres, Juan Escobar · 2013 · Anales de la Facultad de Medicina
Wyzwania terapii otępienia w chorobie Alzheimera
Tomasz Gabryelewicz, Monika Mandecka · 2013 · DOAJ (DOAJ: Directory of Open Access Journals)
Pharmacokinetic Modeling to Simulate the Concentration-Time Profiles After Dermal Application of Rivastigmine Patch
Sachiko Mita, Masayuki Yamaguchi, Gilbert Y. Lefèvre · 2016 · Journal of Pharmaceutical Sciences
Service innovations: a dedicated drug treatment service for dementia
Bart Sheehan, Karim Saad · 2006 · Psychiatric Bulletin
Donepezil in More Advanced Alzheimer's Disease
Nathan W. Rawls · 2005 · The Consultant Pharmacist
Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
JC Sharma · 2002 · International Journal of Clinical Practice
Review on Molecular Targeting, Pharmacological Action, and Advanced Biopharmaceutical Aspects for the Management of Alzheimer’s Disease
Ram Ajay Gupta, Rajni Rajni, Kamal Shah, Hitesh Kumar Dewangan · 2025 · Current Pharmaceutical Design
Alzheimer's Disease and the Disablement Process: Directions for Future Research
Kara Bottiggi Dassel · 2009 · Physical & Occupational Therapy In Geriatrics
Pharmacological Management of Dementia—An Overview
Reetika Dikshit, Sagar Karia, Abha Thakurdesai, Heena Merchant, Avinash De Sousa · 2021 · Springer eBooks
Neuroprotective strategies in Alzheimer’s disease
Frank M. Longo, Stephen M. Massa · 2004 · Neurotherapeutics
Neuroprotection of Multitargeted Phytochemicals against Alzheimer: A Desperate Need from Nature
Ashwani K. Dhingra, Bhawna Chopra · 2022 · The Natural Products Journal
Expanding the role of alpha lipoic acid for psychiatric and neurological health
Ishu Garg, Harish Kumar, Raj Kumari, Anupama Singh, Ravi Maurya, Rashi Pandey, Shruti Bhatt · 2025 · Journal of Asian Natural Products Research
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Steve Pedrini, Mike Morici, Ralph Nigel Martins · 2019 · Wiley eBooks
La maladie d’Alzheimer : perspectives thérapeutiques
Bruno Dubois, Leonardo Cruz de Souza, Gilles Allali, Michel Kalafat, Marie Sarazin · 2008 · Bulletin de l Académie Nationale de Médecine
Neurosurgical Management and Modifiable Risk Factors of Neurocognitive Decline
Ali A. Mohamed, Garrett Flynn, Christopher W. Haff, Edwin Mouhawasse, Steven Faragalla, Brandon Peter Lucke-Wold · 2024 · Preprints.org
Design and Synthesis of Multi Target Compounds for the Treatment of Alzheimer's Disease
Rizzo, Stefano <1979> · 2009 · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna)
Interactions between neuronal nicotinic acetylcholine receptors, N-Methyl-Aspartate receptors and beta-amyloid in the brain of genetically modified mice : Implications for Alheimer´s disease
Christina Unger Lithner · 2005 · Figshare
Rivastigmine for Treatment of AD
Martin Rhys Farlow · 2004 · Humana Press eBooks
Amyloid imaging in Alzheimer´s disease and mild cognitive impairment by Positron Emission Tomography
Anton Forsberg · 2008 · Figshare
Revised NICE guidance on drugs for Alzheimer's disease and its impact on patients and carers
Helen Hudson · 2007 · British Journal of Neuroscience Nursing
Beta-amyloid processing and alpha7 neuronal nicotinic acetylcholine receptors in Alzheimer s disease-related mouse models : Interactive mechanisms with focus on new drug targets
Monika M. Hedberg · 2009 · Figshare